UW Medicine seeks participants for trial of drug to treat monkeypox

UW Medicine seeks participants for trial of drug to treat monkeypox

UW Medicine researchers are seeking participants for a Phase 3 clinical trial of a drug used to treat monkeypox.

The drug, tecovirimat, has been approved by the US Food and Drug Administration to treat smallpox, and researchers want to see if the drug is also safe and effective in treating monkeypox.

“There is an urgent need for treatments for monkeypox, and this study will help us gain critical information about the safety and efficacy of tecovirimat in treating this infection,” said Dr. Rachel Bender Ignacio, a physician-scientist and assistant professor of allergies and infectious diseases at the University of Washington School of Medicine. “People living in the Seattle area who have monkeypox have the opportunity to make a huge contribution by participating in this study.”

The trial aims to enroll at least 500 adults infected with monkeypox and will include people with severe disease and those at risk of severe disease, including pregnant women, children, people with underlying immune deficiencies and people with active inflammatory skin conditions.

Participants will be followed for at least eight weeks through virtual and in-person visits to determine if tecovirimat works better than a placebo.

Those interested in enrolling in the study should contact UW Positive Research by email (positiveresearch@uw.edu) or voice/text at 206-773-7129.

#Medicine #seeks #participants #trial #drug #treat #monkeypox

Leave a Comment

Your email address will not be published.